Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early

1351 - Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort


07 Oct 2016


Breast cancer, early


Xavier Pivot


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


X. Pivot1, J. Pierga2, S. Delaloge3, P. Fumoleau4, H. Bonnefoi5, T. Bachelot6, C. Jouannaud7, H. Bourgeois8, M. Rios9, P. Soulie10, J.P. Jacquin11, S. Lavau-Denes12, P. Kerbrat13, C. Faure Mercier14, I. Pauporte14, J. Gligorov15, E. Curtit16, J. Henriques17, S. Paget-Bailly17, G. Romieu18

Author affiliations

  • 1 Oncology, CHU Besançon, Hôpital Jean Minjoz, 25000 - Besançon/FR
  • 2 Medical Oncology, Institut Curie, 75248 - Paris/FR
  • 3 Dept. Of Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 4 Oncology, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 5 Oncology, Institut Bergonié Unicancer, 33076 - Bordeaux/FR
  • 6 Oncology, Centre leon Berrard, 69373 - Lyon/FR
  • 7 Oncology, Institut Jean Godinot, Reims/FR
  • 8 Oncology, Clinique Victor Hugo Le Mans, Le Mans/FR
  • 9 Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy/FR
  • 10 Oncology, Centre Paul Papin, Angers/FR
  • 11 Oncology, Institut Lucien Neuwirth, saint priest en jarred/FR
  • 12 Oncology, CHU Limoges - Hopital du Cluzeau, Limoges/FR
  • 13 Oncology, Centre Eugene - Marquis, Rennes/FR
  • 14 Research, Institut National du Cancer, Boulogne-Billancourt/FR
  • 15 Oncologie Medicale, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 16 Oncology, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
  • 17 Biostatistic, CHU Besançon, Hôpital Jean Minjoz, Besançon/FR
  • 18 Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1351


Several adjuvant clinical trials in early HER2 positive breast cancer have assessed either sequential or concomitant incorporation of trastuzumab with chemotherapy. Only the NCCTG-N9831 trial prospectively compared the two modalities and whether their results didn't demonstrate a statistical significant difference, the authors have recommended the concurrent regimen with taxane chemotherapy instead of the sequential modality on the basis of a positive risk-benefit ratio. This present research assessed those two modalities sequential versus concomitant in the PHARE/SIGNAL cohort.


PHARE was a randomized phase III clinical trial (NCT00381901) and SIGNAL (RECF1098) was a prospective study specifically designed for GWAS analyses. The comparison in the HER2-positive group of adjuvant trastuzumab and chemotherapy modalities was based on a propensity score methodology applying the inverse probability of treatment weighting method (IPTW) in the cox regression model. Overall Survival (OS) and Disease Free Survival (DFS) were estimated using the Kaplan-Meier method and comparisons between groups were based on the log rank test.


The SIGNAL/PHARE cohort included 11,728 breast cancer cases; 5,502 of them with HER2-positive tumour: 34.5% (1897/5502) were treated by sequential and 65.5% (3605/5502) by concomitant modality of administration for taxane-chemotherapy and trastuzumab. The adjusted comparison found similar OS (HR = 1.01; 95% CI: 0.86-1.19) and similar DFS (HR = 1.08; 95%CI 0.96-1.21).


These results suggest that the sequential administration of trastuzumab given after the completion of adjuvant chemotherapy might be as valid as the concomitant administration of trastuzumab and taxane chemotherapy in the adjuvant setting.

Clinical trial identification

NCT00381901 & RECF1098

Legal entity responsible for the study

French national Cancer Institute (INCa)


French national Cancer Institute (INCa)


X. Pivot: Honorarium for consultant with Roche, Novartis. J.Y. Pierga: Research funding from Roche.

S. Delaloge, T. Bachelot, J.P. Jacquin, G. Romieu, J. Gligorov: Consultant with honorarium from Roche

P. Fumoleau: Honorariums from Roche, GSK, Avenues, Johnson&Johnson. P. Kerbrat: honorarium from Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings